Lexaria Bioscience Corp.
LEXX
$0.62
$0.000.36%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.83% | 28.85% | -39.65% | -0.35% | -23.75% |
| Total Depreciation and Amortization | -15.38% | -24.74% | 313.04% | -77.00% | 61.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.35% | -31.79% | 209.26% | 43.86% | 21.97% |
| Change in Net Operating Assets | 251.37% | 5.87% | -133.06% | 687.36% | -201.78% |
| Cash from Operations | 62.76% | 26.27% | -139.27% | 45.05% | -44.10% |
| Capital Expenditure | -- | -- | -- | 100.00% | 42.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 96.77% | -713.92% | 30.47% | -111.36% | 50.38% |
| Cash from Investing | 96.77% | -713.92% | 30.47% | 26.19% | 45.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 14,336.75% | -99.73% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | 14,336.75% | -99.73% | -- |
| Foreign Exchange rate Adjustments | -153.27% | -71.24% | 139.03% | -2,878.13% | -252.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 188.87% | -48.60% | -16.65% | -201.96% | 180.56% |